Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04760288
Title A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC)
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

thyroid gland medullary carcinoma

Therapies

Cabozantinib

Pralsetinib

Vandetanib

Age Groups: adult | child | senior
Covered Countries ESP

Additional content available in CKB BOOST